Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About ZIMV Interactive Breakdown Better Bets vs. ZIMV Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

ZimVie (ZIMV)

Market Price (10/31/2025): $19.0 | Market Cap: $532.5 Mil
Sector: Health Care | Industry: Health Care Equipment

ZimVie (ZIMV)

Market Price (10/31/2025): $19.0
Market Cap: $532.5 Mil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%		  Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 65x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 44x
1   Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.2%, Rev Chg QQuarterly Revenue Change % is -0.1%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.2%
0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%
1 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 65x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 44x
2 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.2%, Rev Chg QQuarterly Revenue Change % is -0.1%
3 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.2%

Market Valuation & Key Metrics

ZIMVS&P 500
REVENUE GROWTHPOOR
Rev LTM ($ Bil)0.4
Rev Chg Q-0.1%6.5%
Rev Chg LTM-2.2%5.4%
Rev Chg 3Y Avg15.7%5.3%
PROFITABILITYVERY POOR
Op Inc LTM ($ Bil)0.0
CFO LTM ($ Bil)0.0
Net Inc LTM ($ Bil)-0.0
Op Mgn LTM1.4%18.7%
CFO/Rev LTM2.7%20.3%
Net Inc Mgn-4.4%12.7%
VALUATIONHIGH
P/S1.23.2
P/CFO44.515.3
P/FCF94.820.3
P/E-27.423.6
STABILITYGOOD
Debt/Equity0.440.21
Cash/Assets0.090.07

ZIMV Stock

   
   
   
   
   
   
   
Factor Drivers of Stock Movement
null

null
null

null
null

null

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
ZIMV Return---90%-21%-100%�
Peers Return30%25%-12%2%13%-3%61%
S&P 500 Return16%27%-19%24%23%16%110%

Monthly Win Rates [3]
ZIMV Win Rate--33%67%33%- 
Peers Win Rate43%53%37%47%48%56% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
ZIMV Max Drawdown----43%-26%- 
Peers Max Drawdown-20%-9%-36%-20%-17%-11% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: EW, MASI, ATRC, UFPT, CUPR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique KeyEventZIMVS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-81.0%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven427.1%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days

Compare to EW, MASI, ATRC, UFPT, CUPR


In The Past

ZimVie's stock fell -81.0% during the 2022 Inflation Shock from a high on 4/19/2022. A -81.0% loss requires a 427.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About ZimVie (ZIMV)

Better Bets than ZimVie (ZIMV)

 ZIMVBetter Performance than ZIMV
MetricValueIndustry (Health Care Equipment)
Rev Chg LTM-2.2%ABT (6.4%), ISRG (22.2%), BSX (21.4%), SYK (11.4%), MDT (5.0%)
Rev Chg 3Y Avg15.7%ISRG (16.3%), DXCM (17.3%), PODD (26.1%), PEN (16.7%), GMED (44.7%)
Op Mgn LTM1.4%ABT (17.6%), ISRG (29.3%), BSX (18.3%), SYK (19.7%), MDT (19.4%)
CFO/Rev LTM2.7%ABT (20.8%), ISRG (30.8%), BSX (23.2%), SYK (20.0%), MDT (20.9%)
FCF/Rev LTM1.3%ABT (15.8%), ISRG (23.6%), BSX (17.5%), SYK (16.9%), MDT (15.5%)
Total Yield-3.7%ABT (8.3%), ISRG (1.5%), BSX (1.7%), SYK (3.0%), MDT (7.1%)
 ZIMVBetter Performance than ZIMV
MetricValueAll Other Sectors
Rev Chg LTM-2.2%NVDA (71.6%), AAPL (6.0%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%)
Rev Chg 3Y Avg15.7%NVDA (92.0%), AVGO (24.0%), META (17.3%), PLTR (25.7%), GE (15.7%)
Op Mgn LTM1.4%NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM2.7%NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM1.3%NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield-3.7%NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)
 Best Bets In Health Care Sector
 ZIMVRPRX HALO CPRX BMY LNTH PBH BIIB PFE EW ILMN
What You Pay           
P/E-27.315.314.112.315.414.014.013.612.811.812.4
P/EBIT64.78.111.010.59.39.69.010.110.329.210.3
What You Get           
Rev Chg Q-0.1%7.7%40.8%19.4%2.8%-4.1%-6.6%2.8%10.3%11.9%-4.8%
Rev Chg LTM-2.2%3.0%35.0%28.5%1.3%5.7%0.6%4.8%13.5%9.1%-3.3%
Rev Chg 3Y Avg15.7%0.8%35.5%49.9%1.0%34.3%0.8%-0.9%-12.4%3.0%-3.0%
FCF/Rev 3Y Avg-2.4%113.4%43.4%38.9%29.0%26.1%21.6%17.0%13.8%11.9%9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopic
0DASHBOARDS 
1How Low Can ZimVie Stock Really Go?Return

Trade Ideas

Select past ideas related to ZIMV. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.2%4.2%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.3%16.3%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		3.8%3.8%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.0%14.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.5%13.5%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.2%4.2%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.3%16.3%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		3.8%3.8%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.0%14.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.5%13.5%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PRAXPraxis Precision Medicines279.1%161.2%
2INBXInhibrx Biosciences131.0%409.8%
3PUMPProPetro99.6%16.2%
4DYNDyne Therapeutics88.4%-0.0%
5VICRVicor85.4%89.2%
6CELCCelcuity74.6%503.2%
7GLUEMonte Rosa Therapeutics73.5%87.5%
8NVTSNavitas Semiconductor72.1%251.8%
9LUMNLumen Technologies70.3%94.7%
10BALYBallys63.4%4.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical-62.9%5106.3%
2LRNStride-53.8%-35.8%
3FMCFMC-51.0%-66.6%
4FIFiserv-48.3%-68.3%
5NFENew Fortress Energy-43.6%-91.9%
6VGVenture Global-41.7% 
7OGNOrganon-40.2%-55.0%
8VRNSVaronis Systems-39.5%-21.2%
9ITGRInteger-38.5%-52.2%
10LENZLENZ Therapeutics-37.9%5.5%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for ZimVie

Financials

ZIMVEWMASIATRCUFPTCUPRMedian
NameZimVie Edwards .Masimo AtriCure UFP Tech.Cuprina  
Mkt Price-83.48141.5434.09185.280.8883.48
Mkt Cap0.549.07.71.61.4-1.6
Rev LTM4435,6851,848500589-589
Op Inc LTM61,588121-3497-97
FCF LTM6578134873-73
FCF 3Y Avg-159977-2045-45
CFO LTM127951773683-83
CFO 3Y Avg12867132955-55

Growth & Margins

ZIMVEWMASIATRCUFPTCUPRMedian
NameZimVie Edwards .Masimo AtriCure UFP Tech.Cuprina  
Rev Chg LTM-2.2%9.1%8.0%16.3%41.0%-9.1%
Rev Chg 3Y Avg15.7%3.0%10.5%18.2%30.2%-15.7%
Rev Chg Q-0.1%11.9%7.9%17.1%37.2%-11.9%
QoQ Delta Rev Chg LTM-0.0%2.9%1.5%4.1%7.5%-2.9%
Op Mgn LTM1.4%27.9%6.5%-6.8%16.6%-6.5%
Op Mgn 3Y Avg1.1%29.5%8.9%-7.2%15.6%-8.9%
QoQ Delta Op Mgn LTM1.3%0.2%1.1%0.5%-0.2%-0.5%
CFO/Rev LTM2.7%14.0%9.6%7.3%14.2%-9.6%
CFO/Rev 3Y Avg1.7%17.2%7.3%1.5%11.4%-7.3%
FCF/Rev LTM1.3%10.2%7.3%1.7%12.3%-7.3%
FCF/Rev 3Y Avg-2.4%11.9%4.4%-5.3%9.1%-4.4%

Valuation

ZIMVEWMASIATRCUFPTCUPRMedian
NameZimVie Edwards .Masimo AtriCure UFP Tech.Cuprina  
Mkt Cap0.549.07.71.61.4-1.6
P/S1.28.64.23.32.4-3.3
P/EBIT64.729.2-40.7-55.615.1-15.1
P/E-27.311.8-16.7-44.721.3--16.7
P/CFO44.561.643.544.717.1-44.5
Total Yield-3.7%8.5%-6.0%-2.2%4.7%--2.2%
Dividend Yield0.0%0.0%0.0%0.0%0.0%-0.0%
FCF Yield 3Y Avg-1.3%1.1%1.0%-1.1%2.4%-1.0%
D/E0.40.00.10.00.1-0.1
Net D/E0.3-0.10.1-0.00.1-0.1

Returns

ZIMVEWMASIATRCUFPTCUPRMedian
NameZimVie Edwards .Masimo AtriCure UFP Tech.Cuprina  
1M Rtn-7.3%-4.1%-3.3%-7.2%-6.4%-4.1%
3M Rtn-5.3%-8.0%-2.9%-18.2%-88.9%-8.0%
6M Rtn-11.0%-13.5%16.4%-12.7%-81.5%-12.7%
12M Rtn-21.6%-0.9%-2.1%-32.4%--1.5%
3Y Rtn-15.3%7.6%-19.1%97.4%-11.4%
1M Excs Rtn-7.7%-2.4%-2.1%-8.8%-17.8%-2.4%
3M Excs Rtn--4.1%-17.4%-10.3%-27.6%-98.6%-17.4%
6M Excs Rtn--10.7%-35.2%-5.3%-34.5%-103.3%-34.5%
12M Excs Rtn-4.7%-16.6%1.4%-50.7%--7.6%
3Y Excs Rtn--79.4%-71.9%-88.9%31.4%--75.7%

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date7/30/20255/8/20252/26/202510/30/20248/1/20245/8/20242/28/202411/1/20238/2/20235/3/20233/1/202311/9/2022
Key Financials Quarterly            
Total Revenue117112112103117118113105119120-221215
Ebitda131371076122628265714
Operating Income442-3-21-5-1-2-422-8
Net Income-4-1-12-2-4-8-335-5-23-30-301
EPS-0.14-0.05-0.43-0.08-0.15-0.29-12.66-0.19-0.89-1.14-1.160.03
Key Financials TTM            
Total Revenue TTM443444450451453455457123232348463404
Ebitda TTM4337303551729313712510679113
Operating Income TTM61-2-9-7-7-111682-1715
Net Income TTM-19-20-26-349-352-371-393-89-83-68-64-94
Growth Rates Quarterly            
Total Revenue Growth-0.1%-5.2%-1.4%-2.0%-1.5%-1.8%151.1%-50.9%-49.4%-48.9%21.1%-10.5%
EBITDA Growth87.9%123.2%-41.6%-62.3%-75.9%-77.7%-78.4%85.2%239.6%14101.1%-37.4%766.1%
Operating Income Growth333.2%314.1%130.6%-416.9%-0.9%124.1%-124.8%93.3%78.7%83.9%-60.1%66.0%
Net Income Growth1.7%81.0%96.5%55.1%82.8%74.1%-1003.5%-712.4%-168.3%-16.8%50.0%102.7%
Margins Quarterly            
EBITDA Margin10.9%11.7%6.4%9.6%5.8%5.0%10.8%24.9%23.7%21.9%-6.6%
Operating Income Margin3.3%3.3%1.5%-2.8%-1.4%0.7%-4.7%-0.5%-1.4%-3.1%--3.8%
Net Income Margin-3.4%-1.3%-10.6%-2.2%-3.4%-6.6%-296.2%-4.8%-19.7%-24.9%-0.4%
Cash & Debt            
Total Cash7067756779447275666668116
Total Debt235233233234249523522543550552546583
Net Debt / (Cash)164166158167171479450468483486477467
Cash Flows Quarterly            
FCF from Operations3-142113-1221230-7-93
Cash Flows TTM            
FCF from Operations TTM121214143633377-13272555
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC1.5%1.4%0.7%-0.9%-0.7%0.3%-1.6%-0.2%-0.3%-1.1%6.7%-2.7%
Return on Invested Capital (ROIC) TTM            
ROIC TTM0.6%0.1%-0.2%-0.9%-0.7%-0.5%-0.9%1.2%0.6%0.1%-1.2%1.2%

Price Behavior

ZIMV Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta-0.06-0.020.760.870.921.44
Up Beta0.040.07-8.450.070.201.09
Down Beta-0.460.121.481.091.091.56
Up Capture2%-3%587%252%162%411%
Bmk +ve Days13233574144420
Stock +ve Days10212858117374
Down Capture-8%-17%51%124%120%108%
Bmk -ve Days8192952107330
Stock -ve Days7142858123362

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity684,647
Short Interest: % Change Since 930202528.8%
Average Daily Volume258,506
Days-to-Cover Short Interest2.65
Basic Shares Quantity28,026,000
Short % of Basic Shares2.4%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/30/2025-0.5%-0.3%0.1%
5/8/2025-4.7%-5.4%2.2%
2/26/2025-1.7%1.9%-12.1%
10/30/20240.5%6.9%7.7%
8/1/2024-15.2%-13.1%-15.0%
5/8/202410.3%8.5%5.1%
2/28/2024-13.5%-11.2%-15.9%
11/1/202310.5%20.2%47.1%
...
SUMMARY STATS   
# Positive567
# Negative876
Median Positive10.3%7.7%5.1%
Median Negative-8.3%-11.2%-16.1%
Max Positive31.3%25.2%47.1%
Max Negative-44.6%-49.2%-33.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025730202510-Q 6/30/2025
3312025508202510-Q 3/31/2025
12312024226202510-K 12/31/2024
93020241030202410-Q 9/30/2024
6302024801202410-Q 6/30/2024
3312024508202410-Q 3/31/2024
12312023228202410-K 12/31/2023
93020231101202310-Q 9/30/2023
6302023802202310-Q 6/30/2023
3312023503202310-Q 3/31/2023
12312022301202310-K 12/31/2022
93020221109202210-Q 9/30/2022
6302022810202210-Q 6/30/2022
3312022505202210-Q 3/31/2022
12312021331202210-K 12/31/2021
12312020202202210-12B/A 12/31/2020

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.